65,437 trials
Spinal Cord Injury Cervical · Upper Extremity Dysfunction
Primary: Graded and Redefined Assessment of Strength, Sensibility and Prehension Test (GRASSP Test) — 4.5; 19.4 score change before and after — p=<0.000
Eosinophilic Gastritis · Eosinophilic Gastroenteritis
Primary: Relative Change of Peak Eosinophil Counts in the Stomach — -50.28; -3.54 Eosinophil per HPF (EOS/HPF)
Multisystem Inflammatory Syndrome-Children
Primary: Number of Participants Needing Additional Anti-inflammatory Therapy Within the First Week of First Randomization — 10; 10; 14 Participants
Alcohol Use Disorder
Primary: Alcohol Consumption — 37.57; 50.08 Milliliters
Urge Incontinence
Primary: Change in UUI Episodes Per Day — -2.1; -2.73 UUI episodes per day
Gliomas
Primary: Overall Response Rate — 9 percent
Adolescent and Young Adult Cancer Patient
Primary: Treatment Acceptability Questionnaire — 6.02 score on a scale
Recurrent Chronic Lymphocytic Leukemia · Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Follicular Lymphoma
Primary: Best Overall Response Rate (ORR) — 2 Participants
Weight Loss · Diet, Healthy · Cardiovascular Risk Factor
Primary: Percent Weight Change From Baseline to Month 24 — -4.4; -3.8 percentage weight change — p=0.43
Dementia · Depression · Behavior
Primary: Change in Physical Behavioral Symptoms Directed Toward Others — 4; 13; 1 Participants
Sedentary Lifestyle
Primary: Insulin Regulation (mU/L) — 15.93; 15.68; 15.27; 16.72 mU/L
Diffuse Cutaneous Systemic Sclerosis
Primary: The ACR CRISS Composite Score (0-1) at Week 52 — 0.8537; 0.8502 scores on ascale
Major Depressive Disorder
Primary: The Number and Percentage of Patients Reporting Treatment Emergent Adverse Events — 548 Participants
Pancreatic Neoplasms
Primary: Acute Toxicity Rates of Grade 3 or Greater Gastrointestinal and Hematologic Toxicities (as Raw Percentage) — 13.89; 0.00; 2.78; 0.00 percentage of participants
Smoking Behaviors
Primary: Perceived Message Effectiveness for Motivation — 3.18; 2.40; 2.49; 1.49 score on a scale — p=<.001